

## Using electrostatic forces to see which drug is most efficient for Sars Cov-2

part of the enzyme, thereby reducing its efficiency.

is used in SARS-CoV-2.

residues.





## Elvis Lin, Dr. Mojgan Asadi, Dr. Matt Colopy, Prof. Arieh Warshel

Dept of Chemistry, Bridge Institute, University of Southern California, Los Angeles, CA, USA

Bridge UnderGrad Science (BUGS) Summer Research Program

In order to find which drug is most efficient we used PDLD (Protein Dipole Langevin Dipole) calculations that are based on electrostatic forces.

Using PDLD calculations we have determined that the binding affinity for Covid with nirmatrelvir is -6.18 kcal/mol.This concludes that the drug is favorable and inhibitor binds effectively to active site.

Although a potential drug was found, drug designers are constantly trying to find ways to improve designing more effective drugs. A potential solution to improve drug design is finding more advanced computer simulations to improve efficiency and increase accuracy for finding a suitable drug for each disease.

With improved technology, diseases that were considered to be incurable such as cancer and HIV could potentially be cured.

The binding pocket for SARS-CoV-2 is covalently bonded and exhibits the potential for both irreversible and reversible interactions to cysteine.

This bonding pocket is defined not only by the presence of negative and positive charges but also by the distances between neighboring residues.

In our calculations, we kept the distances fixed without imposing any restraints to accommodate the inhibitor within the protein.

To visualize the proteins and gain a better understanding, we used Chimera, which allowed us to find the differences between neighboring residues.

# 2023.

Mehrotra, Neha, and Saurabh Singh. Periodontitis - StatPearls -NCBI Bookshelf, www.ncbi.nlm.nih.gov/books/NBK541126/. Accessed 30 July 2023.

Thank you for Dr.Asadi for taking care of me throughout this whole summer and giving me such valuable information. **CONTACT US** 

bridge.usc.edu/bugs





## **Experimental Findings**

## Summary

## Acknowledgments

OWEN, DAFYDD R., et al. An Oral SARS-COV-2 Mpro Inhibitor Clinical Candidate for the ... - Science, www.science.org/doi/10.1126/science.abl4784. Accessed 24 July